Literature DB >> 21436373

A prospective time-course study on serological testing for human immunodeficiency virus, hepatitis B virus and hepatitis C virus with blood samples taken up to 48 h after death.

Carolin Edler1, Birgit Wulff1, Ann-Sophie Schröder1, Ina Wilkemeyer2, Susanne Polywka3, Thomas Meyer3, Ulrich Kalus2, Axel Pruss2.   

Abstract

The transmission of viral and non-viral infectious pathogens continues to be the most serious of the potential adverse effects of allogenic tissue transplantations. EU Directive 2006/17/EC stipulates that cadaveric blood specimens for serology testing in the context of post-mortem tissue donation must be taken not later than 24 h post-mortem. An expanded time slot would significantly improve the availability of tissue donations, but there are no significant data on the stability of infectious serology assays for anti-human immunodeficiency virus (HIV), anti-hepatitis C virus (HCV), hepatitis B virus (HBV) surface antigen (HBsAg) and anti-HBC core antigen (HBc) in samples collected more than 24 h post-mortem. In this prospective study, serum samples of 30 deceased persons were taken upon admission to the Institute of Forensic Medicine (University Hospital Hamburg-Eppendorf, Germany) and at 12, 24, 36 and 48 h post-mortem. All samples were measured twice, first using the Abbott AxSYM system, and then after ~9 months of storage at -70 °C using the BEP III System with Siemens and Ortho reagents. For HIV, six deceased persons with a pre-mortem HIV history were included. All samples (at committal and at 12, 24, 36, 48 h) were reactive. Indeterminate or false-negative results did not occur. For HCV, 17 deceased persons with a pre-mortem HCV history were included; 16 samples were reactive up to 48 h and one was reactive at 36 h post-mortem (48 h sample was not available). Indeterminate or false-negative results did not occur. For HBV, nine deceased persons were included: five samples were initially positive for HBsAg and remained positive up to 48 h, and eight of the samples were reactive for anti-HBc up to 48 h and one up to 36 h post-mortem (48 h sample was not available). Indeterminate or false-negative results did not occur. These data suggest that infectious serological testing may be extended for blood samples of potential tissue donors collected up to 48 h post-mortem to detect antibodies or antigens for HIV, HBV and HCV.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21436373     DOI: 10.1099/jmm.0.027763-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  11 in total

1.  Validation of the Serological Testing for Anti-HIV-1/2, Anti-HCV, HBsAg, and Anti-HBc from Post-mortem Blood on the Siemens-BEP-III Automatic System.

Authors:  Ulrich Kalus; Ina Wilkemeyer; Gregor Caspari; Jan Schroeter; Axel Pruss
Journal:  Transfus Med Hemother       Date:  2011-11-17       Impact factor: 3.747

2.  Validation of Virus NAT for HIV, HCV, HBV and HAV Using Post-Mortal Blood Samples.

Authors:  Knut Gubbe; Yvonne Scharnagl; Steffi Grosch; Torsten Tonn; Michael Schmidt; Kai M Hourfar; Andreas Karl; Erhard Seifried; Ina Wilkemeyer; Ulrich Kalus
Journal:  Transfus Med Hemother       Date:  2012-11-13       Impact factor: 3.747

3.  Virus NAT for HIV, HBV, and HCV in Post-Mortal Blood Specimens over 48 h after Death of Infected Patients - First Results.

Authors:  Thomas Meyer; Susanne Polywka; Birgit Wulff; Carolin Edler; Ann Sophie Schröder; Ina Wilkemeyer; Ulrich Kalus; Axel Pruss
Journal:  Transfus Med Hemother       Date:  2012-11-19       Impact factor: 3.747

Review 4.  [Bone banks : The state-of-the-art].

Authors:  A Pruß; U Kalus
Journal:  Orthopade       Date:  2018-01       Impact factor: 1.087

5.  Validation of Serological Testing for Anti-Treponema pallidum from Postmortem Blood on the Siemens-BEP(®)-III Automatic System.

Authors:  Ulrich Kalus; Ina Wilkemeyer; Axel Pruss; Gregor Caspari
Journal:  Transfus Med Hemother       Date:  2013-10-17       Impact factor: 3.747

6.  Validation of Spiked Postmortem Blood Samples from Cornea Donors on the Abbott ARCHITECT and m2000 Systems for Viral Infections.

Authors:  Ingo Schmack; Seda Ballikaya; Brigitte Erber; Irina Voehringer; Ulrich Burkhardt; Gerd U Auffarth; Paul Schnitzler
Journal:  Transfus Med Hemother       Date:  2019-09-24       Impact factor: 3.747

7.  Comparison of Total Immunoglobulin G in Ante- and Postmortem Blood Samples from Tissue Donors.

Authors:  Gudrun Larscheid; Tino Schulz; Hermann Herbst; Tina Trögel; Sascha Eulert; Axel Pruß; Jan Schroeter
Journal:  Transfus Med Hemother       Date:  2021-01-05       Impact factor: 3.747

8.  Algorithms for the Testing of Tissue Donors for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus.

Authors:  Axel Pruß; Akila Chandrasekar; Jacinto Sánchez-Ibáñez; Sophie Lucas-Samuel; Ulrich Kalus; Holger F Rabenau
Journal:  Transfus Med Hemother       Date:  2020-12-22       Impact factor: 3.747

9.  Factors affecting the serological testing of cadaveric donor cornea.

Authors:  Anuradha Raj; Garima Mittal; Harsh Bahadur
Journal:  Indian J Ophthalmol       Date:  2018-01       Impact factor: 1.848

10.  Factors influencing the virological testing of cornea donors.

Authors:  Tobias Röck; Robert Beck; Stefan Jürgens; Karl Ulrich Bartz-Schmidt; Matthias Bramkamp; Sebastian Thaler; Daniel Röck
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.